Anavar is a historic trade name for oxandrolone, a synthetic oral anabolic androgenic steroid that once had approved medicine uses in the United States. Oxandrolone was studied for weight restoration, severe burns, corticosteroid related protein loss, osteoporosis related bone pain and several other medical conditions. FDA approval of Oxandrin and its generic versions was withdrawn in 2023.
The current United States record is important: oxandrolone has a genuine medicine history, but FDA no longer treats the withdrawn Oxandrin products as safe and effective for reintroduction under their former approvals. Oxandrolone remains a Schedule III controlled substance and remains prohibited in tested sport.
Sources checked 3 September 2026. Medical and regulatory records change over time. This page does not provide a dose, cycle, stack, product source or personal treatment recommendation.
What is Anavar in medical records?
Anavar is one of the established names associated with oxandrolone. FDA substance records also connect oxandrolone with names including Oxandrin, Lonavar, Provitar and Vasorome.
Oxandrolone has molecular formula C19H30O3, CAS number 53 39 4 and UNII 7H6TM3CT4L. It is a synthetic derivative of testosterone with anabolic and androgenic activity.[1]
| Reference substance | Oxandrolone |
|---|---|
| Historic trade name | Anavar |
| Later United States medicine name | Oxandrin |
| Drug class | Anabolic androgenic steroid |
| Molecular formula | C19H30O3 |
| CAS number | 53 39 4 |
| UNII | 7H6TM3CT4L |
| Current United States medicine approval | Former approvals withdrawn in 2023 |
A chemical identity record does not itself grant medicine approval. Regulatory status belongs to a product application, indication and date.
Was oxandrolone ever FDA approved?
Yes. FDA records show that the 2.5 mg strength associated with NDA 013718 was initially approved on 21 July 1964. The 10 mg Oxandrin strength was approved on 5 November 2001.[3]
This distinction matters because statements that oxandrolone was never FDA approved are incorrect. It had a genuine regulated medicine history before those approvals were later withdrawn.
| Date | Event | Meaning |
|---|---|---|
| 21 July 1964 | 2.5 mg oxandrolone strength initially approved under NDA 013718 | Establishes the original United States medicine record |
| 5 November 2001 | 10 mg Oxandrin strength approved | Expanded the regulated product strengths |
| 2003 to 2005 | Later prescribing information and supplements documented | Preserved indications, warnings and interaction information |
| 2006 | Generic oxandrolone applications approved | Generic products referenced Oxandrin as the listed drug |
| 2019 | Gemini asked FDA to withdraw the Oxandrin application because it was no longer marketed | Commercial withdrawal began a later regulatory review |
| 2023 | FDA withdrew Oxandrin and several generic oxandrolone approvals | The former approved applications ceased to remain approved |
| 13 September 2023 | FDA determined Oxandrin had been withdrawn for reasons of safety or effectiveness | FDA said it would not be considered safe and effective if reintroduced without new evidence |
What was Oxandrin approved to treat?
The former Oxandrin label described oxandrolone as adjunctive therapy for several clinical situations. These included promoting weight gain after major surgery, chronic infection or severe trauma, and in some patients who could not gain or maintain normal weight.
The medicine record also included an adjunct role in reducing protein catabolism associated with prolonged corticosteroid treatment and relief of bone pain associated with osteoporosis.[2]
| Historic use | Clinical purpose | What it does not establish |
|---|---|---|
| Weight loss after major surgery | Support recovery of body weight | A healthy physique indication |
| Weight loss after chronic infection | Support weight restoration in illness | A performance indication |
| Weight loss after severe trauma | Support recovery during a catabolic medical state | Evidence for recreational use |
| Failure to gain or maintain normal weight | Adjunct treatment in selected patients | A general weight gain medicine for healthy people |
| Corticosteroid associated protein catabolism | Offset protein loss during prolonged treatment | A reason to combine steroids without medical supervision |
| Osteoporosis related bone pain | Relief of a defined symptom in the former label | A current preferred osteoporosis treatment |
The presence of an indication in an old label records what the medicine was approved for at that time. It does not override the later withdrawal of approval.
What happened to Oxandrin and generic oxandrolone in 2023?
FDA withdrew approval of NDA 013718 for Oxandrin and several abbreviated applications for generic oxandrolone in 2023. The manufacturers had requested withdrawal of their applications.[4]
A later FDA determination addressed a separate question: whether the products had been withdrawn from sale for reasons of safety or effectiveness. FDA concluded that they had.
This regulatory sequence creates three facts that should remain separate: oxandrolone had previous FDA approval, the named products stopped being marketed, and the former approvals were later withdrawn.
| Statement | Accurate? | Reason |
|---|---|---|
| Oxandrolone was never FDA approved | No | NDA 013718 had approved oxandrolone products |
| Oxandrin remains an FDA approved medicine today | No | The approval was withdrawn in 2023 |
| The product disappeared only for commercial reasons | Incomplete | FDA later determined that withdrawal from sale was for reasons of safety or effectiveness |
| Old clinical studies became invalid after withdrawal | No | The studies remain evidence for the populations and outcomes they actually measured |
| Old approval makes current nonmedical Anavar products approved medicines | No | Approval belonged to specific regulated applications and products |
Why did FDA determine that Oxandrin was withdrawn for safety or effectiveness reasons?
FDA reviewed the historical efficacy record alongside the known safety profile. The agency cited an earlier advisory committee assessment that found inadequate evidence of effectiveness for oxandrolone.
FDA also pointed to serious warnings in the product information. These included peliosis hepatis, liver tumors, cholestatic hepatitis, adverse blood lipid changes, hypercalcemia in some patients with breast cancer and prostate concerns in older men.[3]
The agency stated that the benefit and risk profile was unfavorable without substantial evidence supporting effectiveness. FDA said the products would not be considered safe and effective if brought back under the old evidence base and that new clinical studies would be needed.
Why was oxandrolone researched in people recovering from severe burns?
Major burns can create a prolonged catabolic state with loss of body weight, lean tissue and muscle function. Oxandrolone was studied as one way to reduce that loss and support rehabilitation.
A 1997 randomized study reported faster weight restoration and better physical therapy progress in adults recovering from major burns when oxandrolone was added to high protein nutrition.[5]
A later randomized trial during acute burn care found less body weight loss, improved nitrogen balance and faster healing of a donor skin site in the oxandrolone group.[6]
A multicenter randomized trial in severely burned adults also examined hospital outcomes. Later reviews combined evidence from multiple burn trials.[7]
| Finding | Research context | Transfer limit |
|---|---|---|
| Faster weight restoration | People recovering from major burn related catabolism | Not a healthy bodybuilding population |
| Reduced nitrogen loss | Acute burn care | Does not establish benefit in a person without severe injury |
| Faster donor site healing | Controlled burn rehabilitation research | Cannot be generalized to unrelated wounds |
| Lean mass recovery | Catabolic illness with nutrition and rehabilitation | Does not quantify recreational muscle gain |
The dedicated oxandrolone in burn recovery record covers this research area in more detail.
Was oxandrolone studied for HIV associated weight loss?
Yes. Oxandrolone was studied in men with HIV associated weight loss. A randomized placebo controlled trial involving 262 men assessed changes in body weight and body cell mass.[8]
Weight increased across the study groups, including placebo. Some oxandrolone groups showed greater gains in body weight or body cell mass than placebo.
The same research also found suppression of luteinizing hormone, follicle stimulating hormone and testosterone. Liver enzymes and low density lipoprotein cholesterol increased, while high density lipoprotein cholesterol decreased.
| Outcome | Finding | Interpretation |
|---|---|---|
| Body weight | Increased in every group, with some oxandrolone groups exceeding placebo | Demonstrates why a placebo comparison matters |
| Body cell mass | Some oxandrolone groups had greater increases | Supports anabolic activity in a wasting population |
| Reproductive hormones | Several hormone measures were suppressed | Shows that anabolic effects and endocrine effects occurred together |
| Liver enzymes | Significant increases occurred | Benefit cannot be separated from safety findings |
| Blood lipids | Low density lipoprotein rose and high density lipoprotein fell | Adds cardiovascular risk context |
FDA orphan drug records show that oxandrolone received an orphan designation for adjunctive therapy in HIV wasting, but the FDA database records that indication as not approved for the orphan indication.[9]
What did researchers study in Turner syndrome?
Oxandrolone was studied as an adjunct to growth treatment in girls with Turner syndrome. The research question was height, not athletic performance.
A randomized United Kingdom trial reported a greater final height in girls receiving oxandrolone alongside growth hormone compared with placebo. The study also examined the timing of estrogen treatment.[10]
Other randomized research also assessed oxandrolone alongside growth hormone in Turner syndrome. The balance between added growth and androgen related adverse effects was part of the medical question.
FDA gave oxandrolone an orphan designation for short stature associated with Turner syndrome in 1990. The FDA orphan database states that it was not approved for that orphan indication.[11]
| Record | What it shows | What it does not show |
|---|---|---|
| Randomized clinical research | Oxandrolone was studied for growth outcomes | Automatic FDA approval for that indication |
| Orphan designation | FDA granted development status for a rare disease use | Approval to market the medicine for that indication |
| Final height finding | Some studies found added height benefit | Evidence for healthy adult use |
Was oxandrolone researched in Duchenne muscular dystrophy?
Yes. Oxandrolone was studied in boys with Duchenne muscular dystrophy. A randomized double blind placebo controlled trial assessed muscle strength over six months.[12]
The primary manual muscle strength outcome did not show a statistically significant difference from placebo. A group of quantitative muscle tests did show a difference favoring oxandrolone.
This is a useful example of why one trial should not be reduced to a simple positive or negative label. Different outcomes in the same trial produced different answers.
FDA granted an orphan designation for oxandrolone in Duchenne and Becker muscular dystrophy in 1997. The orphan database records the indication as not FDA approved.[13]
Does an FDA orphan drug designation mean oxandrolone was approved for that disease?
No. Orphan designation and medicine approval are separate regulatory events.
FDA records show several oxandrolone orphan designations. Some were later withdrawn or revoked, and the database specifically marks several proposed uses as not FDA approved for the orphan indication.
| Proposed use | Designation date | FDA orphan approval record |
|---|---|---|
| Short stature associated with Turner syndrome | 5 July 1990 | Not FDA approved for the orphan indication |
| Constitutional delay of growth and puberty | 5 October 1990 | Not FDA approved for the orphan indication |
| HIV wasting syndrome | 6 September 1991 | Not FDA approved for the orphan indication |
| Moderate or severe acute alcoholic hepatitis with malnutrition | 18 March 1994 | Not FDA approved for the orphan indication |
| Duchenne and Becker muscular dystrophy | 22 April 1997 | Not FDA approved for the orphan indication |
A designation can support development of a medicine for a rare condition. It is not evidence that FDA completed the later approval step for that use.
What can oxandrolone’s medical research establish today?
The published research can establish that oxandrolone has measurable biological and clinical effects in specific patient groups. It can also reveal adverse effects and uncertainty.
It cannot turn a person with severe burns, HIV associated weight loss, Turner syndrome or muscular dystrophy into a substitute for a healthy adult seeking physique or performance changes.
| Research finding | Supported interpretation | Unsupported transfer |
|---|---|---|
| Weight recovery after severe burns | Oxandrolone affected recovery in severely injured patients | Predictable muscle gain in a healthy adult |
| Body cell mass in HIV wasting | Anabolic effects occurred in an illness associated with weight loss | A safe recreational result |
| Height change in Turner syndrome | Growth outcomes were affected in a specific pediatric condition | General growth enhancement |
| Muscle testing in Duchenne dystrophy | Some functional outcomes were investigated | A strength estimate for trained adults |
| Historic FDA approval | Oxandrolone once had approved United States products | Current approval after the 2023 withdrawal |
The most useful reading rule is to keep population, indication, outcome and regulatory date attached to every claim.
Is oxandrolone still a controlled substance in the United States?
Yes. The current Drug Enforcement Administration alphabetical controlled substance record lists oxandrolone in Schedule III under controlled substance code 4000. Anavar, Lonavar, Oxandrin, Provitar and Vasorome appear as associated names.[14]
The 2023 withdrawal of FDA medicine approval did not remove oxandrolone from federal controlled substance law.
| System | Question | Current finding |
|---|---|---|
| FDA medicine approval | Does a former Oxandrin application remain approved? | No. The approvals were withdrawn in 2023. |
| FDA safety and effectiveness finding | Could the former product return under its old evidence record? | FDA determined new evidence would be needed. |
| Federal controlled substance law | Is oxandrolone controlled? | Yes. Schedule III. |
| Competitive sport | Is oxandrolone prohibited? | Yes. It is an anabolic agent prohibited at all times. |
Medicine approval, controlled drug law and sport rules answer different questions and should not be treated as interchangeable.
How is oxandrolone controlled in the United Kingdom and Canada?
The United Kingdom Home Office common controlled drug list names oxandrolone as a Class C substance in Schedule 4 Part 2.[15]
Canada includes oxandrolone within the anabolic steroid provisions of Schedule IV of the Controlled Drugs and Substances Act.
| Jurisdiction | Recorded status | Important limit |
|---|---|---|
| United States | Schedule III controlled anabolic steroid | FDA medicine approval is a separate issue |
| United Kingdom | Class C, Schedule 4 Part 2 | Import, possession and supply rules require the full current law |
| Canada | Schedule IV anabolic steroid | Different conduct can carry different legal treatment |
Legal status changes by jurisdiction and conduct. A personal legal question should be checked against current local legislation rather than inferred from a medicine history.
Is oxandrolone prohibited in competitive sport?
Yes. The World Anti Doping Agency 2026 Prohibited List places anabolic androgenic steroids in category S1 and prohibits them at all times. Oxandrolone is included in this anabolic agent framework.[16]
Historic medical use does not create automatic sport permission. An athlete with a genuine medical need must follow the applicable therapeutic use exemption process.
No personal detection period, clearance estimate, masking method or testing workaround is provided here.
Does Anavar’s medical history prove that a product sold today contains oxandrolone?
No. Historic FDA approval belonged to specific regulated products. It does not transfer to a tablet, capsule, powder or liquid sold under the Anavar name today.
A chemical database identifies the reference molecule. A former medicine label describes a named regulated product. Neither authenticates an unrelated product.
| Record | Can establish | Cannot establish |
|---|---|---|
| FDA substance record | Reference identity of oxandrolone | Contents of a product held by a reader |
| Historic NDA | Former regulated medicine history | Current FDA approval after withdrawal |
| Clinical trial | Outcomes in the studied population | Authenticity of a commercial product |
| Seller label | What a seller claims | Independent chemical identity |
| Laboratory analysis | Findings for the tested sample | Composition of every other batch |
Return to Anavar and oxandrolone for the broader substance identity and effect record.
References
- Oxandrolone substance record. United States Food and Drug Administration. Chemical identity, names, formula and identifiers.
- Oxandrin oxandrolone prescribing information. United States Food and Drug Administration. 2003. Historic indications, warnings and prescribing record.
- Determination that Oxandrin was withdrawn from sale for reasons of safety or effectiveness. United States Food and Drug Administration. Federal Register. 13 September 2023.
- Withdrawal of Oxandrin and generic oxandrolone approvals. United States Food and Drug Administration. Federal Register. 28 June 2023.
- Oxandrolone and weight restoration after major burns. Journal of Trauma. 1997. PMID 9253907.
- Anticatabolic and wound healing effects of oxandrolone after severe burn injury. Journal of Critical Care. 2000. PMID 10757193.
- Oxandrolone outcomes in severely burned patients. Journal of Burn Care and Research. 2006. PMID 16566555.
- Oxandrolone in HIV associated weight loss in men. Journal of Acquired Immune Deficiency Syndromes. 2006. PMID 16540931.
- Oxandrolone orphan designation for HIV wasting syndrome. United States Food and Drug Administration. Designated 6 September 1991.
- Oxandrolone and final height in Turner syndrome. BMJ. 2011. PMID 21493672.
- Oxandrolone orphan designation for short stature associated with Turner syndrome. United States Food and Drug Administration. Designated 5 July 1990.
- Randomized oxandrolone trial in Duchenne muscular dystrophy. Neurology. 2001. PMID 11320181.
- Oxandrolone orphan designation for Duchenne and Becker muscular dystrophy. United States Food and Drug Administration. Designated 22 April 1997.
- Controlled substances Orange Book. United States Drug Enforcement Administration. Current 2026 record.
- Common controlled drugs list. United Kingdom Home Office. Oxandrolone is listed as Class C, Schedule 4 Part 2.
- The 2026 Prohibited List. World Anti Doping Agency. Anabolic agents are prohibited at all times.
- Oxandrolone tablets generic approval record. United States Food and Drug Administration. 2006. Identifies Oxandrin as the reference listed drug.